Research graph
References from CAR T‑Cell Therapy as a Bridging Strategy to Second Transplant in Relapsed B‑Cell ALL. Local targets link to admitted publications; unresolved targets remain external evidence.
Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
10.2147/ott.s274551 · 2023 · External reference
Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
10.1038/s41409-020-01101-z · 2021 · External reference
Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia
10.1038/bmt.2012.195 · 2013 · External reference
Management of ALL in adults: 2024 ELN recommendations from a European expert panel
10.1182/blood.2023023568 · 2024 · External reference
Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT
10.1038/bmt.2015.186 · 2015 · External reference
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant
10.1038/sj.bmt.1704645 · 2004 · External reference
Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia
10.1016/j.bbmt.2018.09.016 · 2019 · External reference
Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation
10.1016/j.bbmt.2013.04.014 · 2013 · External reference
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
10.1056/nejmoa1609783 · 2017 · External reference
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
10.1056/nejmoa1509277 · 2016 · External reference
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
10.1002/cncr.33340 · 2021 · External reference
Improving Access to Bone Marrow Transplant and Cellular Therapies
2024 · External reference
A Proportional Hazards Model for the Subdistribution of a Competing Risk
10.1080/01621459.1999.10474144 · 1999 · External reference
Regression Models and Multivariate Life Tables
10.1080/01621459.2020.1713792 · 2021 · External reference
Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
10.1158/1078-0432.ccr-22-2038 · 2023 · External reference
The present and future of CAR T-cell therapy for adult B-cell ALL
10.1182/blood.2023022922 · 2025 · External reference
CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission
10.1182/blood-2025-443 · 2025 · External reference
Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant
10.1186/s40164-018-0125-6 · 2019 · External reference
How risky is a second allogeneic stem cell transplantation?
10.1038/s41375-024-02318-3 · 2024 · External reference
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
10.1016/j.bbmt.2019.04.010 · 2019 · External reference
Efficacy and safety of blinatumomab for the treatment of patients relapsing after allogeneic hematopoietic cell transplantation: a systemic review and meta-analysis
10.1080/16078454.2024.2422151 · 2024 · External reference
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease
10.3324/haematol.2023.284310 · 2024 · External reference
Outcome of second allogeneic hematopoietic cell transplantation in adult patients with relapsed B-cell acute lymphoblastic leukemia in the era of new immunotherapeutic agents
10.1038/s41409-025-02639-6 · 2025 · External reference
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL
10.1200/jco.2023.41.16_suppl.7001 · 2023 · External reference
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
10.1182/bloodadvances.2019000593 · 2019 · External reference
Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: A single-center retrospective analysis
10.1182/blood-2025-6077 · 2025 · External reference
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
10.1182/bloodadvances.2022008981 · 2023 · External reference
Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia
10.1111/ejh.14132 · 2024 · External reference
Recipient-derived vs. donor-derived CAR-T-cell therapy in relapsed B-cell acute lymphoblastic leukemia patients after transplantation: A multi-center retropective study
2025 · External reference
Efficacy and risk of donor-derived CAR-T treatment of relapsed B-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation
10.1016/j.jcyt.2024.05.021 · 2024 · External reference
Long-term follow-up of CD19 chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation
10.1016/j.jcyt.2026.102074 · 2026 · External reference
Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee
10.1016/j.jcyt.2024.11.016 · 2025 · External reference
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy
10.1182/bloodadvances.2024014846 · 2025 · External reference
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
10.1038/s41375-025-02532-7 · 2025 · External reference
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia
10.1200/jco.22.01076 · 2023 · External reference
Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant
2023 · External reference
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
10.1182/blood-2016-07-726588 · 2017 · External reference
